Eli Lilly), a dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist. That’s because of their high cost, the large ...

Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). ...

The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic polypeptide (GIP) tirzepatide, are approved by the U.S. Food & Drug Administration ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

Fractyl Health Inc. has nominated RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...